Back to top anchor

RCT budesonide-formoterol vs salbutamol reliever therapy in childhood asthma

Year:
2020
Duration:
48 months
Approved budget:
$1,439,100.00
Researchers:
Professor Richard Beasley
,
Professor Stuart Dalziel
,
Professor Catherine Byrnes
,
Dr David McNamara
,
Dr Irene Braithwaite
,
Professor Dr Alex Semprini
,
Dr Thomas Hills
,
Associate Professor Matire Harwood
,
Professor Mark Weatherall
,
Dr Andrew Corin
,
Dr Davitt Sheahan
,
Dr Barney Montgomery
,
Professor Andrew Bush
Host:
Medical Research Institute of New Zealand
Health issue:
Respiratory/asthma
Proposal type:
Project
Lay summary
Childhood asthma is a major public health problem in New Zealand. The evidence base for the treatment of childhood asthma is considerably less than for adult asthma. In adults, treatment with a single inhaler that contains both preventer and reliever medications, used as-needed for asthma symptoms, is markedly better at reducing asthma attacks compared to the common approach of taking a reliever-only inhaler as-needed. This new treatment regimen has not been studied in children. If comparable efficacy with as-needed preventer+reliever inhaler treatment is shown in childhood as with adult asthma, then implementation of this approach would markedly reduce the burden of asthma in children. In this randomised controlled trial, undertaken in partnership with community general practitioners, the effect of the combined budesonide+formoterol inhaler taken as-needed will be compared with salbutamol as-needed in children aged 6 to 12.